In a phase 2 trial of 72 patients with HER2-negative recurrent or metastatic breast cancer, oral paclitaxel DHP107 vs IV paclitaxel gave similar response rates (25.0% vs 28.6%), median PFS (5.5 vs 4.7 months) and OS; diarrhoea and nausea were common with DHP107.
RCTn = 72
Rugo et al. OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer